Additional file 1: of Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study

Table S1. Characteristics of patients diagnosed with ER/PR-positive first breast cancer enrolled in the WECARE I and II Study. Table S2. Risk ratios of contralateral breast cancer associated with different aspects of tamoxifen use among participants diagnosed with ER/PR positive first breast cancer in the WECARE I and II Study. Table S3. Risk ratios of ER-positive and ER-negative contralateral breast cancer associated with different aspects of tamoxifen use among participants diagnosed with ER/PR-positive first breast cancer in the WECARE I and II Study. Table S4. Risk ratios of contralateral breast cancer associated with tamoxifen use by patient and tumor characteristics among participants diagnosed with ER/PR positive first breast cancer in the WECARE I and II Study. (DOCX 59 kb

Additional file 1: Table S1. of Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

Association between first breast cancer HR status and CBC, among women not receiving tamoxifen for first diagnosis. In the WECARE Study population of women who had not received tamoxifen for their first breast cancer diagnosis, having an ER-negative first breast cancer or a PR-negative first breast cancer statistically significantly increased the risk of CBC. (DOCX 19 kb